EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Cardiovascular Outcomes among New Users of GLP-1 Receptor Agonists Compared with DPP-4 Inhibitors and Sulfonylureas in Kidney Failure

Benjamin Catanese iD, Cameron Miller iD, Myles Wolf iD, Daniel Edmonston iD

Journal of the American Society of Nephrology · 2026

DOI: 10.1681/asn.0000001061 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of the American Society of Nephrology, 2026. Verfasst von Benjamin Catanese und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl-Peptidase IV Inhibitors, Diabetes Mellitus, Type 2, Sulfonylurea Compounds. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, School of Medicine, Duke University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points Glucagon-like peptide-1 receptor agonists are increasingly used in patients with kidney failure despite trial exclusion. Initiation was associated with a 13% lower risk of cardiovascular events and 17% lower mortality versus dipeptidyl peptidase-4 inhibitors. Initiation was associated with a 10% lower risk of heart failure hospitalization versus dipeptidyl peptidase-4 inhibitors.

Background

Few therapies improve cardiovascular outcomes for people with kidney failure. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) reduce cardiovascular risk in patients with non–dialysis-dependent CKD, but the cardiovascular benefits in patients with kidney failure remain uncertain. The objective of this study was to compare cardiovascular outcomes among patients with kidney failure and type 2 diabetes newly initiated on GLP-1 RA versus other antiglycemic agents.

Methods

We analyzed electronic health records, Medicare claims, and Part D data from the United States Renal Data System (2011–2021) to identify new users of GLP-1 RA ( n =3629), dipeptidyl peptidase-4 inhibitors (DPP4i; n =21,369), and sulfonylureas ( n =32,296) among patients with type 2 diabetes receiving maintenance dialysis. For the primary analysis, we performed 1:1 propensity score matching of GLP-1 RA to DPP4i initiators using 61 covariates. A prespecified secondary analysis compared propensity score–matched initiators of GLP-1 RA and sulfonylureas. The primary outcome was a modified major adverse cardiovascular event (MACE) composite of myocardial infarction, stroke, or all-cause mortality. Secondary outcomes included the individual components of the primary outcome and hospitalizations for heart failure. Cause-specific Cox models were used to estimate hazard ratios (HRs).

Results

Among 3284 matched pairs of GLP-1 RA and DPP4i initiators, GLP-1 RA use was associated with lower risks of MACE (HR, 0.87; 95% confidence interval [CI], 0.78 to 0.97), all-cause mortality (HR, 0.83; 95% CI, 0.74 to 0.94), and heart failure hospitalization (HR, 0.90; 95% CI, 0.83 to 0.99) over up to 2 years of follow-up. Among 2792 matched pairs, GLP-1 RA and sulfonylurea initiators, GLP-1 RA was associated with lower risks of MACE (HR, 0.83; 95% CI, 0.74 to 0.93) and all-cause mortality (HR, 0.80; 95% CI, 0.69 to 0.91).

Conclusions

Among patients with type 2 diabetes receiving maintenance dialysis, GLP-1 RA initiation was associated with lower risk of cardiovascular events and all-cause mortality compared with other commonly prescribed antiglycemic agents. Podcast This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2026_06_12_ASN0000001061.mp3

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsDipeptidyl-Peptidase IV InhibitorsDiabetes Mellitus, Type 2Sulfonylurea CompoundsCardiovascular DiseasesHypoglycemic AgentsRenal InsufficiencyKidney Failure, ChronicHumansMaleFemaleAgedHeart FailureAged, 80 and overUnited StatesHospitalization

Stichwörter der Autor:innen

ESKDGLP-1 receptor agonistscardiovascular diseasecardiovascular eventsdiabetes mellitusheart failure

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsDipeptidyl-Peptidase IV InhibitorsSulfonylurea CompoundsHypoglycemic Agents

Autor:innen und Institutionen

  • Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
  • Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
  • Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
  • Weill Department of Medicine, Weill Cornell Medicine, New York, New York.

ORCID-Profile: Benjamin Catanese, Cameron Miller, Myles Wolf, Daniel Edmonston

Förderung

  • NIDDK NIH HHS
  • School of Medicine, Duke University

Zitieren

APA

Catanese, B., Miller, C., Wolf, M., & Edmonston, D. (2026). Cardiovascular Outcomes among New Users of GLP-1 Receptor Agonists Compared with DPP-4 Inhibitors and Sulfonylureas in Kidney Failure. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.0000001061

Vancouver

Catanese B, Miller C, Wolf M, Edmonston D. Cardiovascular Outcomes among New Users of GLP-1 Receptor Agonists Compared with DPP-4 Inhibitors and Sulfonylureas in Kidney Failure. Journal of the American Society of Nephrology. 2026. doi:10.1681/asn.0000001061

BibTeX
@article{Catanese2026,
  author = {Catanese, Benjamin and Miller, Cameron and Wolf, Myles and Edmonston, Daniel},
  title = {Cardiovascular Outcomes among New Users of GLP-1 Receptor Agonists Compared with DPP-4 Inhibitors and Sulfonylureas in Kidney Failure},
  journal = {Journal of the American Society of Nephrology},
  year = {2026},
  doi = {10.1681/asn.0000001061}
}
Kostenlos starten →